Key result
HFpEF and tricuspid regurgitation share pathophysiology, supporting integrated medical and transcatheter management strategies.
Why the study?
HFpEF and tricuspid regurgitation frequently coexist, sharing risk factors and pathophysiological interactions, raising questions regarding management strategies and the impact of transcatheter TR treatment on HFpEF outcomes.
HFpEF and TR share significant pathophysiological overlap and risk factors, particularly atrial fibrillation, requiring a combined approach of guideline-directed medical therapy for HFpEF and consideration of transcatheter interventions for severe TR.
Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced stage of HFpEF. Management of HFpEF thus may affect the pathophysiology of TR, and the physiologic changes that occur following transcatheter treatment of TR, may also impact symptoms and outcomes in patients with HFpEF. This review discusses these issues and suggests possible management strategies for these patients.
No takes yet. Share an insight, caveat, or question.
Hahn et al. (2024) conducted a review in Heart failure with preserved ejection fraction and tricuspid regurgitation. Guideline-directed management and transcatheter tricuspid valve intervention was evaluated. This state-of-the-art review highlights that heart failure with preserved ejection fraction and tricuspid regurgitation share risk factors and pathophysiology, suggesting integrated management strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: